ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1 Terminated
12 enrolled
EXPAND
Phase 2 Terminated
2 enrolled 8 charts
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1 Terminated
32 enrolled
HPV16 E6 TCR T Cells for Cervical Carcinoma
Phase 1/2 Terminated
5 enrolled
OTT15-04
Phase 4 Terminated
2 enrolled 4 charts
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
BRAVO
Phase 1 Terminated
11 enrolled
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 Terminated
12 enrolled
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Phase 2 Terminated
3 enrolled 10 charts
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Phase 1 Terminated
2 enrolled
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
LuminICE-203
Phase 2 Terminated
25 enrolled 21 charts
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1/2 Terminated
4 enrolled 8 charts
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1 Terminated
1 enrolled
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Phase 1 Terminated
8 enrolled 8 charts
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Phase 1 Terminated
40 enrolled
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Terminated
15 enrolled 27 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
GLEAN-1
Phase 1 Terminated
34 enrolled
AMpLify
Phase 1 Terminated
12 enrolled
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 13 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
ATG Plus Low-dose PT-Cy for GVHD Prevention
Phase 3 Terminated
66 enrolled
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
4 enrolled 10 charts
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled 12 charts
FIRCE-1
Phase 2 Terminated
101 enrolled
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 Terminated
9 enrolled
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Phase 2 Terminated
16 enrolled 11 charts
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
Phase 2 Terminated
10 enrolled 19 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
10 enrolled 14 charts
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Phase 1/2 Terminated
13 enrolled 19 charts
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Phase 1/2 Terminated
38 enrolled 34 charts
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2 Terminated
6 enrolled 15 charts
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Phase 1/2 Terminated
1 enrolled
CHRONOS-4
Phase 3 Terminated
551 enrolled 32 charts
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Phase 1/2 Terminated
2 enrolled 13 charts
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Phase 1 Terminated
12 enrolled 12 charts
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Phase 1 Terminated
5 enrolled 16 charts
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Phase 1 Terminated
3 enrolled
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Phase 1 Terminated
1 enrolled
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 3 Terminated
82 enrolled 11 charts
QUILT-3.080: NANT Pancreatic Cancer Vaccine
Phase 1/2 Terminated
3 enrolled 13 charts